Logo image
Epilepsy Surgery for Pharmacoresistant Temporal Lobe Epilepsy A Decision Analysis
Journal article   Open access   Peer reviewed

Epilepsy Surgery for Pharmacoresistant Temporal Lobe Epilepsy A Decision Analysis

Hyunmi Choi, Randall L. Sell, Leslie Lenert, Peter Muennig, Robert R. Goodman, Frank G. Gilliam and John B. Wong
JAMA : the journal of the American Medical Association, v 300(21), pp 2497-2505
03 Dec 2008
PMID: 19050193
url
https://doi.org/10.1001/jama.2008.771View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Science & Technology
Context Patients with pharmacoresistant epilepsy have increased mortality compared with the general population, but patients with pharmacoresistant temporal lobe epilepsy who meet criteria for surgery and who become seizure- free after anterior temporal lobe resection have reduced excess mortality vs those with persistent seizures. Objective To quantify the potential survival benefit of anterior temporal lobe resection for patients with pharmacoresistant temporal lobe epilepsy vs continued medical management. Design Monte Carlo simulation model that incorporates possible surgical complications and seizure status, with 10 000 runs. The model was populated with health-related quality- of- life data obtained directly from patients and data from the medical literature. Insufficient data were available to assess gamma- knife radiosurgery or vagal nerve stimulation. Main Outcome Measures Life expectancy and quality- adjusted life expectancy. Results Compared with medical management, anterior temporal lobe resection for a 35- year- old patient with an epileptogenic zone identified in the anterior temporal lobe would increase survival by 5.0 years ( 95% CI, 2.1- 9.2) with surgery preferred in 100% of the simulations. Anterior temporal lobe resection would increase qualityadjusted life expectancy by 7.5 quality- adjusted life- years ( 95%, CI, - 0.8 to 17.4) with surgery preferred in 96.5% of the simulations, primarily due to increased years spent without disabling seizures, thereby reducing seizure- related excess mortality and improving quality of life. The results were robust to sensitivity analyses. Conclusion The decision analysis model suggests that on average anterior temporal lobe resection should provide substantial gains in life expectancy and qualityadjusted life expectancy for surgically eligible patients with pharmacoresistant temporal lobe epilepsy compared with medical management.

Metrics

18 Record Views
168 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Clinical Neurology
Logo image